1.87k followers • 11 symbols Watchlist by Yahoo Finance
This basket consists of stocks that benefit from the needs of aging baby boomers.
The Procter & Gamble Company
UnitedHealth Group Incorporated
Royal Caribbean Cruises Ltd.
Service Corporation International
Matthews International Corporation
LifePoint Health, Inc.
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.
Procter & Gamble was up 27.9% YTD on October 16, outperforming the broader markets by a wide margin. PG plans to announce its Q1 earnings on October 22.
Royal Caribbean (RCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If the story of Britain’s high street is one of inexorable decline, then the paperback will be on sale at WHSmith. Paying $400m for gift shop group Marshall brings 170 new US outlets — 59 in airports — lifting WHSmith to third place in the $3bn US airport retail market. To retail analysts, the Marshall deal read particularly well.
We used our Zacks Stock Screener to search for companies within the broader technology sector that also pay a dividend that investors might want to buy as Q3 earnings season heats up...
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Democratic candidates like Kamala Harris and Amy Klobuchar criticized big pharma companies for their role in the opioid crisis.
Wall Street closed Tuesday's trading session at more than three-week high, thanks to better-than expected third quarter 2019 earnings of mostly major American banks.
Efforts to boost productivity, improved pricing and marketing initiatives may have aided Consumer Staples companies in the September quarter, while high costs and macro factors are likely to have hurt.
(Bloomberg) -- The worst may be past for managed-care stocks this year, barring any major surprises, as investors are growing fed up with the political rhetoric in Washington, according to Wall Street analysts.UnitedHealth Group Inc.’s solid third-quarter earnings on Tuesday sparked the sector’s biggest rally in a decade as it helped ease concerns about rising medical costs. While expectations were low heading into the report, the magnitude of the move illustrates just how negative sentiment has gotten. Also roiled by fears of a single-payer system, health insurers appear to have found their footing as investors turned more optimistic about the industry’s business outlook, according to BMO analyst Matthew Borsch.“Until something significantly new happens, I think we’re sort of stabilized for the moment,” he said in a telephone interview. “Investors are kind of fatigued with the political side of this.”The S&P 500 Managed Care Index, which has plunged into two corrections this year, has rebounded to its highest level since August. The gauge jumped as much as 7.5% on Tuesday, the most since November 2009. It’s still trading down 4.7% for the year.Tuesday’s Democratic presidential primary debate will serve as a key test for investors’ renewed optimism. Observers are looking to see whether Senator Elizabeth Warren, who polls show is tied for the lead with former Vice President Joe Biden, will elaborate on her plans for health care. She supports “Medicare-for-All” and has blasted insurers in previous debates, but has remained notably vague on the specifics.It would be difficult to see a reversal of the rally following the debate as investors are familiar with Democrats’ health-care proposals, according to Borsch. Warren could get pushed for more specifics on her plans, but it’s unlikely that will impact investors’ views, he said. “We know what we know at this point.”Other analysts are less sanguine. Bloomberg Intelligence’s Glen Losev said he wouldn’t be surprised to see health insurance stocks pull back from Tuesday’s gains after the debates and stay range-bound in the near term. “The Washington overhang remains and will continue” to be there until a Democratic nominee emerges, he said by telephone.Scott Fidel of Stephens agrees that the sector is not clear of the political uncertainties, saying Tuesday’s rally just reflects investors’ increased comfort with fundamentals.“The market is still pricing in a lot of uncertainty with these stocks, just not at the extreme levels that we had” heading into UnitedHealth’s earnings, Fidel said.To contact the reporter on this story: Tatiana Darie in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Breaking down some of Tuesday's major Q3 earnings results from giants such as JPMorgan Chase and UnitedHealth. A look at what to expect from Netflix's third quarter financials Wednesday. And why Lululemon is a Zacks Rank 1 (Strong Buy) stock...
UnitedHealth (UNH) delivered earnings and revenue surprises of 3.47% and 1.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth's (UNH) higher revenues, strength in both segments -- UnitedHealthcare and Optum -- plus membership growth leads to earnings outperformance.
BOJ Governor Haruhiko Kuroda said on Tuesday the central bank would not hesitate to take additional easing steps if risks to the economy grow and threaten momentum toward its 2% inflation target.
(Bloomberg Opinion) -- Being an enormously profitable industry leader doesn't mean what it used to.Johnson & Johnson and UnitedHealthGroup Inc., the world’s biggest health-care company and health insurer, respectively, reported third-quarter earnings results Tuesday morning that should thrill investors. Both managed to beat Wall Street earnings estimates and boosted full-year profit guidance above expectations as they generated a combined $80 billion in sales. You’d expect shares of well-run blue chips in a defensive sector to be doing well amid recession fears. And yet, even after both J&J and UnitedHealth rose in early trading on their earnings news — with the latter’s stock surging more than 7% — both are substantially trailing the broader market this year as investors focus on policy and legal risks. Making boatloads of cash in today’s environment is the easy part for these companies. The question is their ability to keep doing so in the long run. The performance of lobbyists and, in J&J's case, an armada of lawyers will matter more than the performance of these businesses for some time to come. A big chunk of the Democratic presidential debate Tuesday evening will be devoted to discussing policies that range from unpleasant for both companies to existentially threatening to UnitedHealth.The most threatening proposal from the industry’s standpoint is “Medicare for All,” which would eliminate most private insurance in favor of a government plan and create price pressure throughout the health-care sector. It’s likely too ambitious to have much chance at passing anytime soon, but it can’t be ignored. It’s the preferred policy of Massachusetts Senator Elizabeth Warren, at least for now, and she is looking increasingly like the front-runner. Even the comparatively moderate public options proposed by candidates such as former Vice President Joe Biden would take market share from insurers and pressure profits.While the worst-case scenarios would hurt UnitedHealth more, J&J could very well be more likely to see major policy damage stemming from other initiatives. There's more consensus on drug pricing among Democrats than there is on broader health reform, and that consensus isn’t pharma-friendly. Many Democratic presidential candidates support something similar to House Speaker Nancy Pelosi’s muscular drug price negotiation bill. The nonpartisan Congressional Budget Office recently reported that the legislation would save Medicare $345 billion over seven years and cost drugmakers as much as $1 trillion in revenue over a decade. Action on drug prices is also possible under a broader range of 2020 electoral outcomes; even traditionally more industry-friendly Republicans are keen to act, and President Donald Trump has sounded off on the issue as well and promised action. Add in J&J’s uncertain liabilities from thousands of lawsuits targeting all sides of its business, and it’s easy to see why investors can't focus on fundamentals. Some see this weakness as a buying opportunity, but that bet requires a brave and patient investor. We’re more than a year away from the 2020 election, and J&J’s legal issues will take a long time to resolve. Tangible policy change remains uncertain and distant, but the policy consensus has shifted in an interventionist direction.Even a run of several fabulous quarters can’t change that. To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.